779353-01-4 Usage
Uses
Used in Oncology:
Dinaciclib is used as a CDK inhibitor for the treatment of various types of cancer. It targets CDKs, which are key regulators of cell cycle progression, and inhibits their activity, leading to cell cycle arrest and apoptosis in cancer cells. This makes it a promising therapeutic agent for the treatment of cancer.
Used in Drug Development:
Dinaciclib is currently undergoing development as an oncology therapeutic agent. Its potent and selective inhibition of CDKs makes it a valuable candidate for the treatment of various types of cancer. Researchers are actively investigating its potential efficacy and safety in clinical trials to determine its suitability as a cancer treatment.
Used in Combination Therapy:
Dinaciclib may also be used in combination with other cancer treatments, such as chemotherapy or radiation therapy, to enhance their effectiveness. Its ability to target CDKs and induce cell cycle arrest and apoptosis in cancer cells can potentially synergize with other treatments to improve patient outcomes.
Biological Activity
dinaciclib is a potent cyclin-dependent kinase (cdk) inhibitor with ic50s for cdk2, cdk5, cdk1 and cdk9 at 1 nm, 1 nm, 3 nm, and 4 nm, respectively. [1] it is in phase i or ii
references
[1]parry d., et al. (2010). dinaciclib (sch 727965), a novel and potent cyclin-dependent kinase inhibitor. mol cancer ther (9): 2344- 2353.[2]martin, m. p., et al. (2013). cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. acs chemical biology 8 (11): 2360–5.[3]payton m., et al. (2006). discovery and evaluation of dual cdk1 and cdk2 inhibitors. cancer res 66: 4299-4308.
Check Digit Verification of cas no
The CAS Registry Mumber 779353-01-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,7,9,3,5 and 3 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 779353-01:
(8*7)+(7*7)+(6*9)+(5*3)+(4*5)+(3*3)+(2*0)+(1*1)=204
204 % 10 = 4
So 779353-01-4 is a valid CAS Registry Number.
779353-01-4Relevant academic research and scientific papers
Discovery of dinaciclib (SCH 727965): A potent and selective inhibitor of cyclin-dependent kinases
Paruch, Kamil,Dwyer, Michael P.,Alvarez, Carmen,Brown, Courtney,Chan, Tin-Yau,Doll, Ronald J.,Keertikar, Kerry,Knutson, Chad,McKittrick, Brian,Rivera, Jocelyn,Rossman, Randall,Tucker, Greg,Fischmann, Thierry,Hruza, Alan,Madison, Vincent,Nomeir, Amin A.,Wang, Yaolin,Kirschmeier, Paul,Lees, Emma,Parry, David,Sgambellone, Nicole,Seghezzi, Wolfgang,Schultz, Lesley,Shanahan, Frances,Wiswell, Derek,Xu, Xiaoying,Zhou, Quiao,James, Ray A.,Paradkar, Vidyadhar M.,Park, Haengsoon,Rokosz, Laura R.,Stauffer, Tara M.,Guzi, Timothy J.
scheme or table, p. 204 - 208 (2010/12/20)
Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability paramete
Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives and intermediates
-
Page/Page column 14-15, (2008/06/13)
This application discloses a novel process to synthesize (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives, and intermediates useful in the synthesis thereof. The subject (3-alkyl-5-piperidin-1-yl-3,3a-dihydro-pyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives are useful as cyclin-dependent kinase inhibitor compounds (CDK inhibitors) in pharmaceutical preparations.
